135 related articles for article (PubMed ID: 23448477)
21. Pharmacological and genetic evidence for pre- and postsynaptic D2 receptor involvement in motor responses to nociceptin/orphanin FQ receptor ligands.
Viaro R; Calcagno M; Marti M; Borrelli E; Morari M
Neuropharmacology; 2013 Sep; 72():126-38. PubMed ID: 23643745
[TBL] [Abstract][Full Text] [Related]
22. SR 16435 [1-(1-(bicyclo[3.3.1]nonan-9-yl)piperidin-4-yl)indolin-2-one], a novel mixed nociceptin/orphanin FQ/mu-opioid receptor partial agonist: analgesic and rewarding properties in mice.
Khroyan TV; Zaveri NT; Polgar WE; Orduna J; Olsen C; Jiang F; Toll L
J Pharmacol Exp Ther; 2007 Feb; 320(2):934-43. PubMed ID: 17132815
[TBL] [Abstract][Full Text] [Related]
23. NOP Receptor Signaling Cascades.
Parker KE; Bruchas MR
Handb Exp Pharmacol; 2019; 254():131-139. PubMed ID: 31087192
[TBL] [Abstract][Full Text] [Related]
24. Effects of NOP-Related Ligands in Nonhuman Primates.
Kiguchi N; Ko MC
Handb Exp Pharmacol; 2019; 254():323-343. PubMed ID: 30879202
[TBL] [Abstract][Full Text] [Related]
25. Nociceptin/orphanin FQ (N/OFQ)-evoked bradycardia, hypotension, and diuresis are absent in N/OFQ peptide (NOP) receptor knockout mice.
Burmeister MA; Ansonoff MA; Pintar JE; Kapusta DR
J Pharmacol Exp Ther; 2008 Sep; 326(3):897-904. PubMed ID: 18539652
[TBL] [Abstract][Full Text] [Related]
26. Antinociceptive and morphine modulatory actions of spinal orphanin FQ.
Jhamandas KH; Sutak M; Henderson G
Can J Physiol Pharmacol; 1998 Mar; 76(3):314-24. PubMed ID: 9673795
[TBL] [Abstract][Full Text] [Related]
27. Cebranopadol: a novel potent analgesic nociceptin/orphanin FQ peptide and opioid receptor agonist.
Linz K; Christoph T; Tzschentke TM; Koch T; Schiene K; Gautrois M; Schröder W; Kögel BY; Beier H; Englberger W; Schunk S; De Vry J; Jahnel U; Frosch S
J Pharmacol Exp Ther; 2014 Jun; 349(3):535-48. PubMed ID: 24713140
[TBL] [Abstract][Full Text] [Related]
28. Therapeutic potential of nociceptin/orphanin FQ peptide (NOP) receptor modulators for treatment of traumatic brain injury, traumatic stress, and their co-morbidities.
Al Yacoub ON; Awwad HO; Zhang Y; Standifer KM
Pharmacol Ther; 2022 Mar; 231():107982. PubMed ID: 34480968
[TBL] [Abstract][Full Text] [Related]
29. Endogenous opiates and behavior: 2012.
Bodnar RJ
Peptides; 2013 Dec; 50():55-95. PubMed ID: 24126281
[TBL] [Abstract][Full Text] [Related]
30. A bifunctional nociceptin and mu opioid receptor agonist is analgesic without opioid side effects in nonhuman primates.
Ding H; Kiguchi N; Yasuda D; Daga PR; Polgar WE; Lu JJ; Czoty PW; Kishioka S; Zaveri NT; Ko MC
Sci Transl Med; 2018 Aug; 10(456):. PubMed ID: 30158150
[TBL] [Abstract][Full Text] [Related]
31. Opiate modulating properties of nociceptin/orphanin FQ.
Harrison LM; Grandy DK
Peptides; 2000 Jan; 21(1):151-72. PubMed ID: 10704732
[TBL] [Abstract][Full Text] [Related]
32. In vivo pain-inhibitory role of nociceptin/orphanin FQ in spinal cord.
Inoue M; Kawashima T; Takeshima H; Calo G; Inoue A; Nakata Y; Ueda H
J Pharmacol Exp Ther; 2003 May; 305(2):495-501. PubMed ID: 12606680
[TBL] [Abstract][Full Text] [Related]
33. Pharmacological characterization of orphanin FQ/nociceptin and its fragments.
Rossi GC; Leventhal L; Bolan E; Pasternak GW
J Pharmacol Exp Ther; 1997 Aug; 282(2):858-65. PubMed ID: 9262352
[TBL] [Abstract][Full Text] [Related]
34. The Orphanin FQ / Nociceptin receptor as a novel drug target in psychiatric disorders.
Reinscheid RK
CNS Neurol Disord Drug Targets; 2006 Apr; 5(2):219-24. PubMed ID: 16611094
[TBL] [Abstract][Full Text] [Related]
35. NOP-Targeted Nonpeptide Ligands.
Zaveri NT; Meyer ME
Handb Exp Pharmacol; 2019; 254():37-67. PubMed ID: 31119463
[TBL] [Abstract][Full Text] [Related]
36. Knock-In Mice with NOP-eGFP Receptors Identify Receptor Cellular and Regional Localization.
Ozawa A; Brunori G; Mercatelli D; Wu J; Cippitelli A; Zou B; Xie XS; Williams M; Zaveri NT; Low S; Scherrer G; Kieffer BL; Toll L
J Neurosci; 2015 Aug; 35(33):11682-93. PubMed ID: 26290245
[TBL] [Abstract][Full Text] [Related]
37. Pharmacological Assays for Investigating the NOP Receptor.
Malfacini D; Caló G
Handb Exp Pharmacol; 2019; 254():69-89. PubMed ID: 30725284
[TBL] [Abstract][Full Text] [Related]
38. Current and Future Therapeutic Options in Pain Management: Multi-mechanistic Opioids Involving Both MOR and NOP Receptor Activation.
Coluzzi F; Rullo L; Scerpa MS; Losapio LM; Rocco M; Billeci D; Candeletti S; Romualdi P
CNS Drugs; 2022 Jun; 36(6):617-632. PubMed ID: 35616826
[TBL] [Abstract][Full Text] [Related]
39. Nociceptin Opioid Receptor (NOP) as a Therapeutic Target: Progress in Translation from Preclinical Research to Clinical Utility.
Zaveri NT
J Med Chem; 2016 Aug; 59(15):7011-28. PubMed ID: 26878436
[TBL] [Abstract][Full Text] [Related]
40. [The role of nociceptin in opioid regulation of brain functions].
Shamakina IY; Shagiakhmetov FS; Anokhin PK; Kohan VS; Davidova TV
Biomed Khim; 2021 Jan; 67(1):5-16. PubMed ID: 33645518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
